Aura Biosciences Inc
NASDAQ:AURA
| US |
|
Fubotv Inc
NYSE:FUBO
|
Media
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
C
|
C3.ai Inc
NYSE:AI
|
Technology
|
| US |
|
Uber Technologies Inc
NYSE:UBER
|
Road & Rail
|
| CN |
|
NIO Inc
NYSE:NIO
|
Automobiles
|
| US |
|
Fluor Corp
NYSE:FLR
|
Construction
|
| US |
|
Jacobs Engineering Group Inc
NYSE:J
|
Professional Services
|
| US |
|
TopBuild Corp
NYSE:BLD
|
Consumer products
|
| US |
|
Abbott Laboratories
NYSE:ABT
|
Health Care
|
| US |
|
Chevron Corp
NYSE:CVX
|
Energy
|
| US |
|
Occidental Petroleum Corp
NYSE:OXY
|
Energy
|
| US |
|
Matrix Service Co
NASDAQ:MTRX
|
Construction
|
| US |
|
Automatic Data Processing Inc
NASDAQ:ADP
|
Technology
|
| US |
|
Qualcomm Inc
NASDAQ:QCOM
|
Semiconductors
|
| US |
|
Ambarella Inc
NASDAQ:AMBA
|
Semiconductors
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
6.81
11.74
|
| Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
|
|
Fubotv Inc
NYSE:FUBO
|
US |
|
|
Bank of America Corp
NYSE:BAC
|
US |
|
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
C
|
C3.ai Inc
NYSE:AI
|
US |
|
|
Uber Technologies Inc
NYSE:UBER
|
US |
|
|
NIO Inc
NYSE:NIO
|
CN |
|
|
Fluor Corp
NYSE:FLR
|
US |
|
|
Jacobs Engineering Group Inc
NYSE:J
|
US |
|
|
TopBuild Corp
NYSE:BLD
|
US |
|
|
Abbott Laboratories
NYSE:ABT
|
US |
|
|
Chevron Corp
NYSE:CVX
|
US |
|
|
Occidental Petroleum Corp
NYSE:OXY
|
US |
|
|
Matrix Service Co
NASDAQ:MTRX
|
US |
|
|
Automatic Data Processing Inc
NASDAQ:ADP
|
US |
|
|
Qualcomm Inc
NASDAQ:QCOM
|
US |
|
|
Ambarella Inc
NASDAQ:AMBA
|
US |
This alert will be permanently deleted.
Aura Biosciences Inc
Aura Biosciences Inc
Selling, General & Administrative
Aura Biosciences Inc
Selling, General & Administrative Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Selling, General & Administrative | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Aura Biosciences Inc
NASDAQ:AURA
|
Selling, General & Administrative
-$19.8m
|
CAGR 3-Years
-68%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Abbvie Inc
NYSE:ABBV
|
Selling, General & Administrative
-$14B
|
CAGR 3-Years
-5%
|
CAGR 5-Years
-15%
|
CAGR 10-Years
-9%
|
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Selling, General & Administrative
-$5.6B
|
CAGR 3-Years
-2%
|
CAGR 5-Years
-6%
|
CAGR 10-Years
-8%
|
|
|
Amgen Inc
NASDAQ:AMGN
|
Selling, General & Administrative
-$7.5B
|
CAGR 3-Years
-9%
|
CAGR 5-Years
-8%
|
CAGR 10-Years
-5%
|
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Selling, General & Administrative
-$1.5B
|
CAGR 3-Years
-22%
|
CAGR 5-Years
-19%
|
CAGR 10-Years
-17%
|
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Selling, General & Administrative
-$2.9B
|
CAGR 3-Years
-23%
|
CAGR 5-Years
-16%
|
CAGR 10-Years
-21%
|
|
Aura Biosciences Inc
Glance View
Aura Biosciences, Inc. is a clinical-stage oncology company. The company is headquartered in Cambridge, Massachusetts and currently employs 52 full-time employees. The company went IPO on 2021-10-29. The firm operates a platform, which focuses on ocular and urologic oncology. Its platform enables targeting of a range of solid tumors using Virus-Like Particles (VLPs) that can be conjugated with drugs or loaded with nucleic acids to create Virus-Like Drug Conjugates (VDCs). The firm's VDC platform offers a range of portfolio of targeted oncology therapeutics. The company engaged in developing AU-011 for the treatment of early-stage disease, which includes small melanomas and indeterminate lesions. Its product candidate, AU-011 consists of a human papilloma virus (HPV)-derived VLP conjugated to thousands of infrared laser-activated molecules. VDC prevents the conjugation from interfering with tumor binding enabling its selectivity to specifically modified HSPGs on tumor cells but not to normal cells. In addition, the Company is developing AU-011 for the treatment of non-muscle invasive bladder cancer (NMIBC).
See Also
What is Aura Biosciences Inc's Selling, General & Administrative?
Selling, General & Administrative
-19.8m
USD
Based on the financial report for Dec 31, 2023, Aura Biosciences Inc's Selling, General & Administrative amounts to -19.8m USD.
What is Aura Biosciences Inc's Selling, General & Administrative growth rate?
Selling, General & Administrative CAGR 3Y
-68%
Over the last year, the Selling, General & Administrative growth was -9%. The average annual Selling, General & Administrative growth rates for Aura Biosciences Inc have been -68% over the past three years .
You don't have any saved screeners yet
